Trial population
Between 10 and 23 August 2022, 511 participants received 50 µg of mRNA-1273.222. These participants had previously received the primary series of 100 µg mRNA-1273 and a first booster dose of 50 µg mRNA-1273, ≥3 months before enrollment (Fig. 